GLAXOSMITHKLINE PLC Form 6-K February 11, 2015

FORM 6-K/A

## SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of athe Securities Exchange Act of 1934

For period ending February 2015

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

\_

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

## GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

In accordance with DTR 3.1.4R(1)(a) and (c) GlaxoSmithKline plc ('GSK') was advised on 11 February 2015 that the following Directors, Persons Discharging Managerial Responsibilities and Connected Person acquired GSK Ordinary Shares ('Shares') on 10 February 2015, at a price of 1505.46 pence per Ordinary Share, through GSK's Share Reward Plan (the 'Plan'):

Director/PDMR	Number of SharesNumber of Shares under the personalunder the matching contribution elementelement of the plan of the plan (GSK contribution)	
Sir Andrew Witty	8	8
Mr R G Connor	8	8
Mr S Dingemans	8	8
Mr N Hirons	8	8
Mr D S Redfern	8	8
Ms C Thomas	8	8
Mr P C Thomson	8	8
Dr P J T Vallance	9	9
Ms E Walmsley	8	8
Mrs V A Whyte	8	8

Connected person Number of Shares Number of Shares

under the personalunder the matching contribution elementelement of the plan of the plan (GSK contribution)

Mrs K Thomson 4 4

(Connected person of Mr

P C Thomson)

V A Whyte Company Secretary 11 February 2015

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report t	to be
signed on its behalf by the undersigned, thereunto duly authorised.	

GlaxoSmithKline plc (Registrant)

Date: February 11, 2015

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc